Siren Biotechnology Appoints Former FDA CBER Oncology Branch Chief Peter Bross to Advisory Board

Siren Biotechnology appointed Peter Bross, MD, former Chief of the Oncology Branch at the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research, to its Clinical and Scientific Advisory Board, the company said on October 14, 2026. Bross brings more than 25 years of FDA experience in oncology drug development and clinical review of advanced biologics, including gene and cell therapies. The announcement was distributed by GlobeNewswire.

Peter Bross's FDA Career and Advisory Role

Bross joined the FDA in 1999 and most recently served as Chief of the Oncology Branch within CBER's Office of Therapeutic Products, formerly the Office of Tissues and Advanced Therapies. During his FDA career, he provided clinical leadership in the review of investigational and marketing applications for therapies addressing solid tumors and hematologic malignancies, including immunotherapies, oncolytic viruses, cancer vaccines, targeted therapies, and other novel oncology products. He previously served as a clinical reviewer in the Division of Oncology Drug Products within the FDA's Center for Drug Evaluation and Research. Bross earned his medical degree from the University of Virginia School of Medicine and completed fellowship training in hematology and oncology at The George Washington University.

"Peter's experience is unusually well matched to what Siren is building," said Nicole Paulk, PhD, Founder, CEO, and President of Siren Biotechnology. "We are not developing a conventional gene therapy or a conventional immunotherapy. We are creating a new therapeutic modality at the intersection of both."

Bross joins as Siren advances SRN-101, its lead investigational Universal AAV Immuno-Gene Therapy candidate for recurrent high-grade glioma, into clinical development under two cleared Investigational New Drug applications. "Siren is doing something genuinely novel at the intersection of gene therapy and oncology," Bross said. "The company has paired a differentiated scientific approach with the development discipline required to bring a new therapeutic modality into clinical evaluation."

Siren's Regulatory Milestones for SRN-101

According to akta.pro company records, the FDA cleared Siren's first IND application for SRN-101 in recurrent high-grade glioma in January 2026, the first FDA-cleared IND for an AAV-based therapy in an oncology indication. The FDA granted Fast Track Designation to SRN-101 for recurrent high-grade glioma in February 2026. Siren revealed SRN-101 as its lead clinical asset in November 2024, accompanied by FDA Orphan Drug Designation and Rare Pediatric Disease Designation. The same records show Siren has raised $31.6 million in total funding across five rounds, most recently an $8 million grant led by the California Institute for Regenerative Medicine in June 2026.

UCSF Trial and Next Steps

In March 2026, Siren entered a partnership with the University of California, San Francisco for an investigator-initiated Phase 1 clinical trial of SRN-101 in recurrent high-grade glioma led by Dr. Nicholas Butowski, Professor of Neurological Surgery and Neuro-Oncology. Siren provides study drug and collaborates in support of the trial. The company's website describes its Universal AAV Immuno-Gene Therapy platform.